Výsledky vyhledávání - "Hugo Arlegui"

Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines

Autor: Vincent Bauchau, Gaëlle Nachbaur, Hugo Arlegui, Kaatje Bollaerts, Nicolas Praet, Bernard Bégaud, Francesco Salvo

Publikováno v: Drug Safety
Drug Safety, Springer Verlag, 2020, 43 (11), pp.1089-1104. ⟨10.1007/s40264-020-00984-7⟩

Introduction Understanding the balance between the benefits and risks of vaccination is essential to ensure informed and adequate public health decision making. Quantitative benefit–risk models (qBRm) represent useful tools to help decision makers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74f97f1d3271f1fd65cb81223483a8c8
http://europepmc.org/articles/PMC7575467

Zobrazit plný text záznamu

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

Autor: Olivier Chosidow, Hervé Bachelez, Thomas Bettuzzi, Marie Beylot-Barry, Pascal Joly, Alain Dupuy, Florence Tubach, Emmanuel Mahé, Nathalie Beneton, Manuelle Viguier, Marie-Aleth Richard, Denis Jullien, Hugo Arlegui, Emilie Sbidian, Carle Paul

Publikováno v: Acta Dermato-Venereologica
Acta Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩
Acta Dermato-Venereologica, Society for Publication of Acta Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩

International audience; Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb6c5c9a9d7cf0f0d17ade051452590
https://hal.science/hal-03660920/file/Bettuzzi_document.pdf

Zobrazit plný text záznamu

Impact de l’épidémie de COVID-19 lors de la 1ère vague sur les patients de la cohorte PSOBIOTEQ traités pour psoriasis cutané

Autor: Pascal Joly, Manuelle Viguier, Hugo Arlegui, Denis Jullien, Alain Dupuy, Marie Beylot-Barry, Emmanuel Mahé, Nathalie Beneton, Yann De Rycke, Hervé Bachelez, Florence Tubach, Marilyn Zago, Emilie Sbidian, Olivier Chosidow, Carle Paul, Marie-Aleth Richard

Publikováno v: Annales de Dermatologie et de Vénéréologie-FMC

Introduction La propagation de COVID-19 a amené la France à se confiner une 1ère fois du 17 mars au 11 mai 2020. Cette maladie potentiellement grave a confronté les patients atteints de psoriasis et recevant un traitement systémique, ainsi que l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c15410f40ad9da7c747f8856e1969f4
https://doi.org/10.1016/j.fander.2021.09.325

Zobrazit plný text záznamu

First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq

Autor: Carle Paul, Alain Dupuy, Pascal Joly, Caroline Giboin, Denis Jullien, Manuelle Viguier, Emilie Sbidian, Hervé Bachelez, Florence Assan, Hugo Arlegui, Olivier Chosidow, Emmanuel Mahé, Marie Beylot-Barry, Nathalie Beneton, and Psobioteq, Florence Tubach, Marie-Aleth Richard

Publikováno v: Dermatology
Dermatology, Karger, 2021, 237 (3), pp.338-346. ⟨10.1159/000513398⟩
Dermatology, 2021, 237 (3), pp.338-346. ⟨10.1159/000513398⟩

Background: Obesity is associated with an increased risk of psoriasis. Objective: In this study, we examined whether body mass index (BMI) is taken into account when choosing first-line biologic therapy for psoriasis. Methods: In this cohort study, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6345bc20f9be150692da3f03379214cf
https://hal.archives-ouvertes.fr/hal-03156232

Zobrazit plný text záznamu

Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)

Autor: Kaatje Bollaerts, Hugo Arlegui, Nicolas Praet, Bernard Bégaud, Gaëlle Nachbaur, Vincent Bauchau

Publikováno v: Drug Safety
Drug Safety, Springer Verlag, 2020, 43 (11), pp.1105-1120. ⟨10.1007/s40264-020-00982-9⟩

Introduction Quantitative benefit-risk models (qBRm) applied to vaccines are increasingly used by public health authorities and pharmaceutical companies as an important tool to help decision makers with supporting benefit-risk assessment (BRA). Howev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8ba31bdc1f662b026222ab22fadf877
http://hdl.handle.net/20.500.12278/23779

Zobrazit plný text záznamu

Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review

Autor: Nicolas Praet, Bernard Bégaud, Hugo Arlegui, Gaëlle Nachbaur

Publikováno v: Open Forum Infectious Diseases
Open Forum Infectious Diseases, Oxford University Press, 2020, 7 (4), pp.ofaa087. ⟨10.1093/ofid/ofaa087⟩

BackgroundAlthough rotavirus vaccines have proven to prevent the risk of rotavirus gastroenteritis (RVGE) in children under 5 years old, they are also associated with an increased transient risk of intussusception (IS). Several quantitative benefit-r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a72aee4b75e3e6f8eb320aa1c209b4
http://hdl.handle.net/20.500.12278/23781

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání